Molecular Biology of Huntington's Disease (HD) and HD-Like Disorders

Genetics of Movement Disorders

Volumn , Issue , 2003, Pages 365-383

  Rubinsztein, David C ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33846214868     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012566652-7/50035-6     Document Type: Chapter

References (185)

1. Almqvist E., Elterman D., MacLeod P., Hayden M. High incidence rate and absent family histories in one quarter of patients newly diagnosed with Huntington disease in British Columbia. Clin. Genet. 2001, 60:198-205.
2. Almqvist E., Spence N., Nichol K., Andrew S.E., Vesa J., Peltonen L., Anvret M., Goto J., Kanazawa I., Goldberg Y.P., Hayden M.R. Ancestral differences in the distribution of the delta 2642 glutamic acid polymorphism is associated with varying CAG repeat lengths on normal chromosomes: insights into the genetic evolution of Huntington disease. Hum. Mol. Genet. 1995, 4:207-214.
3. Ambrose C.M., Duyao M.P., Barnes G., Bates G.P., Lin C.S., Srinidhi J., Baxendale S., Hummerich H., Lehrach H., Altherr M., Wasmuth J., Buckler A., Church D., Housman D., Berks M., Micklem G., Durbin R., Dodge A., Read A., Gusella J., MacDonald M.E. Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat. Som. Cell Mol. Genet. 1994, 20:27-38.
4. American College of Human Genetics and the American Society of Human Genetics Huntington Disease Genetic Testing Working Group ACMG/ASHG Statement Laboratory Guidelines for Huntington disease genetic testing. Am. J. Hum. Genet. 1998, 62:1243-1247.
5. Antonini A., Leenders K.L., Spiegel R., Meier D., Vontobel P., Weigell-Weber M., Sanchez-Pernaute R., de Yebenez J.G., Boesiger P., Weindl A., Maguire R.P. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 1996, 119:2085-2095.
6. Aronin N., Kim M., Laforet G., DiFiglia M. Are there multiple pathways in the pathogenesis of Huntington's disease. Philos. Trans. R. Soc. London, Ser. 1999, 354:995-1003.
7. Augood S.J., Faull R.L., Love D.R., Emson P.C. Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: a detailed cellular in situ hybridization study. Neuroscience 1996, 72:1023-1036.
8. Aylward E.H., Codori A.M., Barta P.E., Pearlson G.D., Harris G.J., Brandt J. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch. Neurol. 1996, 53:1293-1296.
9. Aylward E.H., Anderson N.B., Bylsma F.W., Wagster M.V., Barta P.E., Sherr M., Feeney J., Davis A., Rosenblatt A., Pearlson G.D., Ross C.A. Frontal lobe volume in patients with Huntington's disease. Neurology 1998, 50:252-258.
10. Aylward E.H., Codori A.M., Rosenblatt A., Sherr M., Brandt J., Stine O.C., Barta P.E., Pearlson G.D., Ross C.A. Rate of caudate atrophy inpresymptomatic and symptomatic stages of Huntington's disease. Mov. Disord. 2000, 15:552-560.
11. Bachoud-Levi A.C., Remy P., Nguyen J.P., Brugieres P., Lefaucheur J.P., Bourdet C., Baudic S., Gaura V., Maison P., Haddad B., Boisse M.F., Grandmougin T., Jeny R., Bartolomeo P., Dalla, Barba G., Degos J.D., Lisovoski F., Ergis A.M., Pailhous E., Cesaro P., Hantraye P., Peschanski M. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 2000, 356:1975-1979.
12. Bailey C.K., McCampbell A., Madura K., Merry D.E. Biochemical analysis of high molecular weight protein aggregates containing expanded polyglutamine repeat androgen receptor. Am. J. Hum. Genet. Suppl. 1998, 63:A8.
13. Barth A.L., McKenna M., Glazewski S., Hill P., Impey S., Storm D., Fox K. Upregulation of cAMP response element-mediated expression during experience-dependent plasticity in adult neocortex. J. Neurosci. 2000, 20:4206-4216.
14. Beal M.F., Kowall N.W., Ellison D.W., Mazurek M.F., Swartz K.J., Martin J.B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986, 321:168-171.
15. Beal M.F., Ferrante R., Swartz K.J., Kowall N.W. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J. Neurosci. 1989, 11:1649-1659.
16. Beal M.F. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?. Ann. of Neurol. 1992, 31:119-130.
17. Beal M.F., Hantraye P. Novel therapies in the search for a cure for Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:3-4.
18. Becher M.W., Rubinsztein D.C., Leggo J., Wagster M.V., Stine O.C., Ranen N.G., Franz M.L., Abbott M.H., Sherr M., MacMillan J.C., Barron L., Porteous M., Harper P.S., Ross C.A. Dentatorubral and pallidoluysian atrophy (DRPLA). Clinical and neuropathological findings in genetically confirmed North American and European pedigrees. Mov. Disord. 1997, 12:519-530.
19. Becher M.W., Kotzuk J.A., Sharp A.H., Davies S.W., Bates G.P., Price D.L., Ross C.A. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol. Dis. 1998, 4:387-397.
20. Beitel L.K., Trifiro M.A., Pinsky L. Spinobulbar muscular atrophy. Analysis of Triplet Repeat Disorders 1998, 85-103. Bios Scientific Publishers, Oxford. D.C. Rubinsztein, M.R. Hayden (Eds.).
21. Bence N.F., Sampat R.M., Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001, 292:1552-1555.
22. Borlongan C.V., Koutouzis T.K., Sanberg P.R. 3-Nitropropionic acid animal model and Huntington's disease. Neurosci. Biobehav. Rev. 1997, 21:289-293.
23. Brandt J., Strauss M.E., Larus J., Jensen B., Folstein S.E., Folstein M.F. Clinical correlates of dementia and disability in Huntington's disease. J. Clin. Neuropsychiatry 1984, 6:401-412.
24. Brouillet E., hantraye P., Ferrante R.J., Dolan R., Leroy-Willig A., Kowall N.W., Beal M.F. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc. Nat. Acad. Sci. U.S.A. 1995, 92:7105-7109.
25. Butterworth N.J., Williams L., Bullock J.Y., Love D.R., Faull R.L., Dragunow M. Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum. Neuroscience 1998, 87:49-53.
26. Cariello L., de Cristofaro T., Zanetti L., Cuomo T., Di Maio L., Campanella G., Rinaldi S., Zanetti P., Di Lauro R., Varrone S. Transglutaminase activity is related to CAG repeat length in patients with Huntington's disease. Hum. Genet. 1996, 98:633-635.
27. Cattaneo E., Rigamonti D., Goffredo D., Zuccato C., Squitieri F., Sipione S. Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci. 2001, 24:182-188.
28. Carmichael J., Chatellier J., Woolfson A., Milstein C., Fersht A.R., Rubinsztein D.C. Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:9701-9705.
29. Chai Y., Koppenhafer S.L., Shoesmith S.J., Perez M.K., Paulson H.L. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Hum. Mol. Genet. 1999, 8:673-682.
30. Chai Y., Stacia L.K., Bonini N.M., Paulson H.L. Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease. J. Neurosci. 1999, 19:10,338-10,347.
31. Chen M., Ona V.O., Li M., Ferrante R.J., Fink K.B., Zhu S., Bian J., Guo L., Farrell L.A., Hersch S.M., Hobbs W., Vonsattel J.P., Cha J.H., Friedlander R.M. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 2000, 6:797-801.
32. Chun W., Lesort M., Tucholski J., Ross C.A., Johnson G.V. Tissue transglutaminase does not contribute to the formation of mutant huntingtin aggregates. J. Cell Biol. 2001, 153:25-34.
33. Chun W., Lesort M., Tucholski J., Faber P.W., MacDonald M.E., Ross C.A., Johnson G.V. Tissue transglutaminase selectively modifies proteins associated with truncated mutant huntingtin in intact cells. Neurobiol. Dis. 2001, 8:391-404.
34. Coles R., Caswell R., Rubinsztein D.C. Functional analysis of the Huntington's disease (HD) gene promoter. Hum. Mol. Genet. 1998, 7:791-800.
35. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., Lansbury P.T. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:571-576.
36. Cooper J.K., Schilling G., Peters M.F., Herring W.J., Sharp A.H., Kaminsky Z., Masone J., Khan F.A., Delanoy M., Borchelt D.R., Dawson V.L., Dawson T.M., Ross C.A. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum. Mol. Genet. 1998, 7:783-790.
37. Coyle J.T., Schwarcz R. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 1976, 263:244-246.
38. Cummings C.J., Mancini M.A., Antalffy B., DeFranco D.B., Orr H.T., Zoghbi H.Y. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat. Genet. 1998, 19:148-154.
39. Cummings C.J., Reinstein E., Sun Y., Antalffy B., Jiang Y., Ciechanover A., Orr H.T., Beaudet A.L., Zoghbi H.Y. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron 1999, 24:879-892.
40. Craufurd D. Predictive testing for trinucleotide repeat disorders. Analysis of Triplet Repeat Disorders 1998, 305-323. Bios Scientific Publishers, Oxford. D.C. Rubinsztein, M.R. Hayden (Eds.).
41. Curtis A.R., Fey C., Morris C.M., Bindoff L.A., Ince P.G., Chinnery P.F., Coulthard A., Jackson M.J., Jackson A., McHale D.P., Hay D., Barker W.A., Markham A.F., Bates D., Curtis A., Burn J. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat. Genet. 2001, 28:350-354.
42. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., Scherzinger E., Wanker E.E., Mangiarini L., Bates G.P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997, 90:537-548.
43. Davies S.W., Beardsall K., Turmaine M., DiFiglia M., Aronin N., Bates G.P. Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions?. Lancet 1998, 351:131-133.
44. de la Monte S.M., Vonsattel J.P., Richardson E.P. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J. Neuropathol. Exp. Neurol. 1998, 47:516-525.
45. De Souza E.B., Whitehouse P.J., Folstein S.E., Price D.L., Vale W.W. Corticotropin-releasing hormone (CRH) is decreased in the basal ganglia in Huntington's disease. Brain Res. 1987, 437:355-359.
46. de Vries B.B., Arts W.F., Breedveld G.J., Hoogeboom J.J., Niermeijer M.F., Heutink P. Benign hereditary chorea of early onset maps to chromosome 14q. Am. J. Hum. Genet. 2000, 66:136-142.
47. Dewhurst K., Oliver J.E., McKnight A.L. Sociopsychiatric consequences o Huntington's disease. Br. J. Psychiatry 1970, 116:255-258.
48. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.-P., Aronin N.A. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
49. Di Maio L., Squitieri F., Napolitano G., Campanella G., Trofatter J.A., Conneally P.M. Suicide risk in Huntington's disease. J. Med. Genet. 1993, 30:293-295.
50. Dragunow M., Faull R.L., Lawlor P., Beilharz E.J., Singleton K., Walker E.B., Mee E. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes. Neuroreport 1995, 6:1053-1057.
51. Duyao M.P., Auerbach A.B., Ryan A., Persichetti F., Barnes G.T., McNeil S.M., Ge P., Vonsattel J.-P., Gusella J.F., Joyner A.L., MacDonald M.E. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 1995, 269:407-410.
52. Dyer R.B., McMurray C.T. Mutant protein in Huntington disease is resistant to proteolysis in affected brain. Nat. Genet. 2001, 29:270-278.
53. Faber P.W., Alter J.R., MacDonald M.E., Hart A.C. Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc. Natl. Acad. Sci. U.S.A. 1999, 96(1):179-184.
54. Falush D., Almqvist E.W., Brinkmann R.R., Iwasa Y., Hayden M.R. Measurement of mutational flow implies both a high newmutation rate for Huntington disease and substantial underascertainment of late-onset cases. Am. J. Hum. Genet. 2001, 68:373-385.
55. Feigin A., Kieburtz K., Como P., Hickey C., Claude K., Abwender D., Zimmerman C., Steinberg K., Shoulson I. Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov. Dis. 1996, 11:321-323.
56. Fernandez-Funez P., Nino-Rosales M.L., de Gouyon B., She W.C., Luchak J.M., Martinez P., Turiegano E., Benito J., Capovilla M., Skinner P.J., McCall A., Canal I., Orr H.T., Zoghbi H.Y., Botas J. Identification of genes that modify ataxin-1-induced neurodegeneration. Nature 2001, 408(6808):101-106.
57. Ferrante R.J., Andreassen O.A., Jenkins B.G., Dedeoglu A., Kuemmerle S., Kubilus J.K., Kaddurah-Daouk R., Hersch S.M., Beal M.F. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 2000, 20:4389-4397.
58. Fesus L., Thomazy V. Searching for function of tissue transglutaminase: its possible involvement in biochemical pathway of programmed cell death. Adv. Exp. Bio. 1988, 231:119-134.
59. Folstein S., Abbott M.H., Chase G.A., Jensen B.A., Folstein M.F. The association of affective disorders with Huntington's disease in a case series and in families. Psychol. Med. 1983, 13:537-542.
60. Folstein S.E., Chase G., Wahl W.E., McDonnell A.M., Folstein M.F. Huntington's disease in Maryland: clinical aspects of racial variation. Am. J. Hum. Genet. 1987, 41:168-179.
61. Freeman T.B., Cicchetti F., Hauser R.A., Deacon T.W., Li X.J., Hersch S.M., Nauert G.M., Sanberg P.R., Kordower J.H., Saporta S., Isacson O. Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:13,877-13,882.
62. Gervais F.G., Singaraja R., Xanthoudakis S., Gutekunst C.-A., Leavitt B.R., Metzler M., Hackam A., Tam J., Vaillancourt J.P., Houtzager V., Rasper D.M., Roy S., Hayden M.R., Nicholson D.W. Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi. Nat. Cell Biol. 2002, 4:95-105.
63. Goedert M. Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. Philos. Trans. R. Soc. London. Ser. B 1999, 354:1101-1118.
64. Goldberg Y.P., Nicholson D.W., Rasper D.M., Kalchman M.A., Koide H.B., Graham R.K., Bromm M., Kazemi-Esfarjani P., Thornberry N.A., Vaillancourt J.P., Hayden M.R. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat. Genet. 1996, 13:442-449.
65. Grafton S.T., Mazziotta J.C., Pahl J.J., St.George-Hyslop P., Haines J.L., Gusella J., Hoffman J.M., Baxter L.R., Phelps M.E. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. Arch. Neurol. 1992, 49:1161-1167.
66. Gu M., Gash M.T., Mann V.M., Javoy-Agid F., Cooper M., Schapira A.H.V. Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 1996, 39:385-389.
67. Guidetti P, Charles V., Chen E.Y., Reddy P.H., Kordower J.H., Whetsell W.O., Schwarez R., Tagle D.A. Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production. Exp. Neurol. 2001, 169:340-350.
68. Harper P.S. Huntington's Disease 1996, W.B. Saunders, London. 2nd edition.
69. He F., Zhang S., Qian F., Zhang C. Delayed dystonia with striatal CT lucencies induced by a mycotoxin (3-nitropropionic acid). Neurology 1995, 45:2178-2183.
70. Heiser V., Scherzinger E., Boeddrich A., Nordhoff E., Lurz R., Schugardt N., Lehrach H., Wanker E.E. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:6739-6744.
71. Hendrick J.P., Hartl F.U. Molecular chaperone functions of heat-shock proteins. Ann. Rev. Biochem. 1993, 62:349-384.
72. Ho L.W., Brown R., Maxwell M., Wyttenbach A., Rubinsztein D.C. Wild type huntingtin reduces the cellular toxicity of mutant huntingtin in mammalian cell models of Huntington's disease. J. Med. Genet. 2001, 38:450-452.
73. Ho M., Chelly J., Carter N., Danek A., Crocker P., Monaco A.P. Isolation of the gene for McLeod syndrome that encodes a novel membrane transport protein. Cell 1994, 77:869-880.
74. Hodgson J.G., Agopyan N., Gutekunst C.A., Leavitt B., LePiane F., Singaraja R., Smith D.J., Bissada N., McCutcheon K., Nasir J., Jamot L., Li X.J., Stevens M.E., Rosemond E., Roder J.C., Phillips A.G., Rubin E.M., Hersch S.M., Hayden M.R. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 1999, 23:181-192.
75. Holmes S.E., O'Hearn E., Rosenblatt A., Callahan C., Hwang H.S., Ingersoll-Ashworth R.G., Fleisher A., Stevanin G., Brice A., Potter N.T., Ross C.A., Margolis R.L. A repeat expansion in the gene encoding junctophilin-3 is associated with Huntington disease-like 2. Nat. Genet. 2001, 29:377-378.
76. Huang Q., Zhou D., Sapp E., Aizawa H., Ge P., Bird E.D., Vonsattel J.-P., DiFiglia M. Quinolinic acid-induced increases in calbindin D28K immunoreactivity in rat striatal neurons in vivo and in vitro mimic the pattern see in Huntington's disease. Neuroscience 1995, 65:397-407.
77. Huang C.C., Faber P.W., Persichetti F., Mittal V., Vonsattel J.P., MacDonald M.E., Gusella J.F. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Som. Cell Mol. Genet. 1998, 24:217-233.
78. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983. Huntington's Disease Collaborative Research Group.
79. Iannicola C., Moreno S., Oliverio S., Nardacci R., Ciofi-Luzzatto A., Piacentini M. Early alterations in gene expression and cell morphology in a mouse model of Huntington's disease. J. Neurochem. 2000, 75:830-839.
80. Igarashi S., Koide R., Shimohata T., Yamada M., Hayashi Y., Takano H., Date H., Oyake M., Sato T., Sato A., Egawa S., Ikeuchi T., Tanaka H., Nakano R., Tanaka K., Hozumi I., Inuzuka T., Takahashi H., Tsuji S. Suppression of aggregate formation and apoptosis by trahsglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch. Nat. Genet. 1998, 18:111-117.
81. Jana N.R., Tanaka M., Wang Gh., Nukina N. Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity. Hum. Mol. Genet. 2000, 9:2009-2018.
82. 1H NMR spectroscopy. Neurology 1993, 43:2689-2695.
83. Jensen P., Sorensen S.A., Fenger K., Bolwig T.G. A study of psychiatric morbidity in patients with Huntington disease, their relatives and controls. Admissions to psychiatric hospitals in Denmark from 1969 to 1991. Br. J. Psychiatry 1993, 163:790-797.
84. Kahlem P., Green H., Dijan P. Transglutaminase action imitates Huntington's disease: Selective polymerization of Huntingtin containing expanded polyglutamine. Mol. Cell 1998, 1:595-601.
85. Kambouris M., Bohlega S., Al-Tahan A., Meyer B.F. Localisation of the gene for a novel autosomal recessive neurodegenerative Huntington-like disorder to 4p15.3. Am. J. Hum. Genet. 2000, 66:445-452.
86. Karpuj M.V., Garren H., Slunt H., Price D.L., Gusella J., Becher M.W., Steinman L. Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:7388-7393.
87. Kazemi-Esfarjani P., Benzer S. Genetic suppression of polyglutamine toxicity in Drosophila. Science 2000, 287:1837-1840.
88. Kieburtz K., Feigin A., McDermott M., Como P., Abwender D., Zimmerman C., Hickey C., Orme C., Claude K., Sotack J., Greenamyre J.T., Dunn C., Shoulson I. A controlled trial of remacemide hydrochloride in Huntington's disease. Mov. Dis. 1996, 11:273-277.
89. Klement I.A., Skinner P.J., Kaytor M.D., Yi H., Hersch S.M., Clark H.B., Zoghbi H.Y., Orr H.T. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 1998, 95:41-53.
90. 10. Ann. Neurol. 1997, 41:160-165.
91. Kremer B., Almqvist E., Theilmann J., Spence N., Telenius H., Goldberg Y.P., Hayden M.R. Sex-dependent mechanisms for expansions and contractions of the CAG repeat on affected Huntington disease chromosomes. Am. J. Hum. Genet. 1995, 57:343-350.
92. Kremer B., Clark C.M., Almqvist E.W., Raymond L.A., Graf P., Jacova C., Mezei M., Hardy M.A., Snow B., Martin W., Hayden M.R. Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. Neurology 1999, 53:1000-1011.
93. Kuwert T., Lange H.W., Langen K.J., Herzog H., Aulich A., Feinendegen L.E. Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. Brain 1990, 113:1405-1423.
94. Leavitt B.R., Guttman J.A., Hodgson J.G., Kimel G.H., Singaraja R., Vogl A.w., Hayden M.R. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. Am. J. Hum. Genet. 2001, 68:313-324.
95. Lecerf J.M., Shirley T.L., Zhu Q., Kazantsev A., Amersdorfer P., Housman D.E., Messer A., Huston J.S. Human singlechain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:4764-4769.
96. Li S.H., Cheng A.L., Li H., Li X.J. Cellular defects and altered gene expression in PC12 cells stably expressing mutant huntingtin. J. Neurosci. 1999, 19:5159-5172.
97. Li H., Li S.H., Johnston H., Shelbourne P.F., Li X.J. Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. Nat. Genet. 2000, 25:385-389.
98. Li H., Li S.H., Yu Z.X., Shelbourne P., Li X.J. Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. J. Neurosci. 2001, 21:8473-8481.
99. Lipe H., Schultz A., Bird T.D. Risk factors for suicide in Huntingtons disease: a retrospective case controlled study. Am. J. Med. Genet. 1993, 48:231-233.
100. Liu Y.F. Expression of polyglutamine-expanded huntingtin activates the SEK1-JNK pathway and induces apoptosis in a hippocampal neuronal cell line. J. Biol. Chem. 1998, 273:28,873-28,877.
101. Ludolph A.C., He F., Spencer P.S., Hammerstad J., Sabri M. 3-Nitropropionic acid-exogenous animal toxin and possible human striatal toxin. Can. J. Neurol. Sci. 1991, 18:492-498.
102. Luthi-Carter R., Strand A., Peters N.L., Solano S.M., Hollingsworth Z.R., Menon A.S., Frey A.S., Spektor B.S., Penney E.B., Schilling G., Ross C.A., Borchelt D.R., Tapscott S.J., Young A.B., Cha J.H., Olson J.M. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet. 2000, 9:1259-1271.
103. McCampbell A., Taylor J.P., Taye A.A., Robitschek J., Li M., Walcott J., Merry D., Chai Y., Paulson H., Sobue G., Fischbeck K.H. CREB-binding protein sequestration by expanded polyglutamine. Hum. Mol. Genet. 2000, 9:2197-2202.
104. MacDonald M.E., Vonsattel J.-P., Shrinidhi J., Couropmitree N.N., Cupples L.A., Bird E.D., Gusella J.F., Myers R.H. Evidence for the GluR6 gene associated with younger onset age of Huntington's disease. Neurology 1999, 53:1330-1332.
105. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
106. Margolis R.L., O'Hearn E., Rosenblatt A., Willour V., Holmes S.E., Franz M.L., Callahan C., Hwang H.S., Troncoso J.C., Ross C.A. A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion. Ann. Neurol. 2001, 50:373-380.
107. Marsh J.L., Walker H., Theisen H., Zhu Y.Z., Fielder T., Purcel L.J., Thompson L.M. Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila. Hum. Mol. Genet. 2000, 9(1):13-25.
108. Martin W.R., Clark C., Ammann W., Stoessl A.J., Shtybel W., Hayden M.R. Cortical glucose metabolism in Huntington's disease. Neurology 1992, 42:223-229.
109. Martindale D., Hackam A., Wieczorek A., Ellerby L., Wellington C., McCutcheon K., Singaraja R., Kazemi-Esfarjani P., Devon R., Kim S.U., Bredesen D.E., Tufaro F., Hayden M.R. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat. Genet. 1998, 18:150-154.
110. McGeer E.G., McGeer P.L., Singh K. Kainate-induced degeneration of neostriatal neurons: dependency upon corticostriatal tract. Brain Res. 1978, 139:381-383.
111. McNeil S.M., Novelletto A., Srinidhi J., Barnes G., Kornbluth I., Albuth M.R., Wasmuth J.J., Gusella J.F., MacDonald M.E., Myers R.H. Reduced penetrance of the Huntington's disease mutation. Hum. Mol. Genet. 1997, 6:775-779.
112. Mende-Mueller L.M., Toneff T., Hwang S.R., Chesselet M.F., Hook V.Y. Tissue-specific proteolysis of Huntingtin (htt) in human brain: evidence of enhanced levels of N- and C-terminal htt fragments in Huntington's disease striatum. J. Neurosci. 2001, 21:1830-1837.
113. Metzler M., Legendre-Guillemin V., Gan L., Chopra V., Kwok A., McPherson P.S., Hayden M.R. HIP1 functions in clathrin-mediated endocytosis through binding to clathrin and AP2. J. Biol. Chem. Aug 21 [epub ahead of print] 2001.
114. Moore R.C., Xiang F., Monaghan J., Han D., Zhang Z., Edstrom L., Anvret M., Prusiner S.B. Huntington Disease Phenocopy Is a Familial Prion Disease. Am. J. Hum. Genet. Oct. 9 [epub ahead of print] 2001.
115. Murphy K.S.J., Carter R.J., Lione L.A., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., Morton A.J. Abnormal synpatic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J. Neurosci. 2000, 20:5115-5123.
116. Nagai Y., Tucker T., Ren H., Kenan D.J., Henderson B.S., Keene J.D., Strittmatter W.J., Burke J.R. Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phase display screening. J. Biol. Chem. 2000, 275:10,437-10,442.
117. Nasir J., Floresco S.B., O'Kusky J.R., Diewert V.M., Richman J.M., Zeisler J., Borowski A., Marth J.D., Phillips A.G., Hayden M.R. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioural and morphological changes in heterozygotes. Cell 1995, 81:811-823.
118. Nicholson D.W., Thornberry N.A. Caspases: Killer proteins. Trends Biochem. Sci. 1997, 22:299-306.
119. Nishiyama K., Kwak S., Takekoshi S., Watanabe K., Kanazawa I. In situ end-labelling detects necrosis of hippocampal pyramidal cells induced by kainic acid. Neurosci. Lett. 1996, 212:139-142.
120. Novelli A., Reilly J.A., Lysko P.G., Henneberry R.C. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res. 1988, 451:205-212.
121. Nucifora F.C., Sasaki M., Peters M.F., Huang H., Cooper J.K., Yamada M., Takahashi H., Tsuji S., Troncoso J., Dawson V.L., Dawson T.M., Ross C.A. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 2001, 291:2423-2428.
122. Ona V.O., Li M., Vonsattel J.-P., Andrews L.J., Khan S.Q., Chung W.M., Frey A.S., Menon A.S., Li X.J., Stieg P.E., Yuan J., Penney J.B., Young A.B., Cha J.H., Friedlander R.M. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 1999, 399:263-267.
123. Ordway J.M., Tallaksen-Greene S., Gutekunst C.A., Bernstein E.M., Cearley J.A., Wiener H.W., Dure L.S., Lindsey R., Hersch S.M., Jope R.S., Albin R.L., Detloff P.J. Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse. Cell 1997, 91:753-763.
124. Orr H.T., Skinner P.J., Klement C.J., Cummings C.J., Zoghbi H.Y. The role of ataxin-1 nuclear expression and aggregates in SCA1 pathogenesis. Am. J. Hum. Genet. Suppl. 1998, 63:A8.
125. Paulson H.L., Perez M.K., Trottier Y., Trojanowski J.Q., Subramony S.H., Das S.S., Vig P., Mandel J.-L., Fischbeck K.H., Pittman R.N. Intranuclear inclusions of expanded polyglutamine protein in spinocerbellar ataxia type 3. Neuron 1997, 19:333-344.
126. Paulson H., Chai Y., Gray-Board G., Bonini N. Misfolding and aggregation in spinocerebellar ataxia type 3: a role for cellular chaperones in glutamine-repeat disease. Am. J. Hum. Genet. Suppl. 1998, 63:A8.
127. Penney J.B., Young A.B., Shoulson I., starosta-Rubenstein S., Snodgrass S.R., Sanchez-Ramos J., Romos-Arroyo M., Gomez F., Penchaszadeh G., Alvir J., Esteves J., DeQuiroz I., Marsol N., Moreno H., Conneally P.M., Bonilla E., Wexler N.S. Huntington disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov. Dis. 1990, 5:93-99.
128. Perutz M.F., Johnson T., Suzuki M., Finch J.T. Glutamine repeats as polar zippers: Their possible role in inherited neurodegenerative diseases. Proc. Nat. Acad. Sci. U.S.A. 1994, 91:5355-5358.
129. Perutz M.F. Glutamine repeats and neurodegenerative diseases: molecular aspects. Trends Biochem. Sci. 1999, 24:58-63.
130. Peters P.J., Ning K., Palacios F., Boshans R., Kazantzev A., Thompson L., Woodman B., Bates G.P., D'Souza-Schorey C. Arfaptin 2 regulates the aggregation of mutant huntingtin protein. Nat. Cell. Biol. Feb 18 [epub ahead of print] 2002.
131. Peyser C.E., Folstein M., Chase G.A., Starkstein S., Brandt J., Cockrell J.R., Bylsma F., Coyle J.T., McHugh P.R., Folstein S.E. Trial of d-alpha-tocopherol in Huntington's disease. Am. J. Psychiatry 1995, 152:1771-1775.
132. Polidori M.C., Mecocci P., Browne S.E., Senin U., Beal M.F. Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex. Neurosci. Lett. 1999, 272:53-56.
133. Portera-Cailliau C., Hedreen J.C., Price D.L., Koliatsos V.E. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J. Neurosci. 1995, 15:3775-3787.
134. Presinger E., Jordan B.M., Kazantsev A., Housman D. Evidence for a recruitment and sequestration mechanism in Huntington's disease. Philos. Trans. R. Soc. London, Ser. B 1999, 354:1029-1034.
135. Rampoldi L., Dobson-Stone C., Rubio J.P., Danek A., Chalmers R.M., Wood N.W., Verellen C., Ferrer X., Malandrini A., Fabrizi G.M., Brown R., Vance J., Pericak-Vance M., Rudolf G., Carre S., Alonso E., Manfredi M., Nemeth A.H., Monaco A.P. A conserved sorting-associated protein is mutant in chorea-acanthocytosis. Nat. Genet. 2001, 28:119-120.
136. n repeats in parent-offspring pairs with Huntington's disease. Am. J. Hum. Genet. 1995, 57:593-602.
137. Ranen N.G., Peyser C.E., Coyle J.T., Bylsma F.W., Sherr M., Day L., Folstein M.F., Brandt J., Ross C.A., Folstein S.E. A controlled trial of idebenone in Huntington's disease. Mov. Disord. 1996, 11:549-554.
138. Rigamonti D., Bauer J.H., De-Fraja C., Conti L., Sipione S., Sciorati C., Clementi E., Hackam A., Hayden M.R., Li Y., Cooper J.K., Ross C.A., Govoni S., Vincenz C., Cattaneo E. Wild-type huntingtin protects from apoptosis upstream of caspase-3. J. Neurosci. 2000, 20:3705-3713.
139. Rigamonti D., Sipione S., Goffredo D., Zuccato C., Fossale E., Cattaneo E. Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing. J. Biol. Chem. 2001, 276:14,545-14,548.
140. Rodda R.A. Cerebellar atrophy in Huntington's disease. J. Neurol. Sci. 1981, 50:47-57.
141. Rosenblatt A., Brinkman R.R., Liang K.Y., Almqvist E.W., Margolis R.L., Huang C.Y., Sherr M., Franz M.L., Abbott M.H., Hayden M.R., Ross C.A. Familial influence on age of onset among siblings with Huntington disease. Am. J. Med. Genet. 2001, 105:399-403.
142. Ross C.A., Hayden M.R. Huntington's Disease. Analysis of Triplet Repeat Disorders 1998, 169-208. Bios Scientific Publishers, Oxford. D.C. Rubinsztein, M.R. Hayden (Eds.).
143. Rubinsztein D.C., Amos W., Leggo J., Goodburn S., Ramesar R.S., Old J., Bontrop R., McMahon R., Barton D.E., Ferguson-Smith M.A. Mutational bias provides a model for the evolution of Huntington's disease and predicts a general increase in disease prevalence. Nat. Genet. 1994, 7:525-530.
144. Rubinsztein D.C., Leggo J., Coles R., Almqvist E., Biancalana V., Cassiman J.-J., Chotai K., Connarty M., Craufurd D., Curtis A., Curtis D., Davidson M.J., Differ A.-M., Dode C., Dodge A., Frontali M., Ranen N.G., Stine O.C., Sherr M., Abbott M.H., Franz M.L., Graham C.A., Harper P.S., Hedreen J.C., Jackson A., Kaplan J.-C., Losekoot M., MacMillan J.C., Morrison P., Trottier Y., Novelletto A., Simpson S.A., Theilmann J., Whittaker J.L., Folstein S.E., Ross C.A., Hayden M.R. Phenotypic characterisation of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am. J. Hum. Genet. 1996, 59:16-22.
145. Rubinsztein D.C., Leggo J., Chiano M., Dodge A., Norbury G., Rosser E., Craufurd D. Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington's disease. Proc. Nat. Acad. Sci. U.S.A. 1997, 94:3872-3876.
146. Rubinsztein D.C., Hayden M.R. Introduction. Analysis of Triplet Repeat Disorders 1998, 1-12. Bios Scientific Publishers, Oxford. D.C. Rubinsztein, M.R. Hayden (Eds.).
147. Sanchez I., Xu C.J., Juo P., Kakizaka A., Blenis J., Yuan J. Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron 1999, 22:623-633.
148. Sapp E., Ge P., Aizawa H., Bird E., Penney J., Young A.B., Vonsattel J.P., DiFiglia M. Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis. Neuroscience 1995, 64:397-404.
149. Sapp E., Penney J., Young A., Aronin N., Vonsattel J.-P., DiFiglia M. Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease. J. Neuropathol. Exp. Neurol. 1999, 58:165-173.
150. Saudou F., Finkbeiner S., Devys D., Greenberg M.E. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998, 95:55-66.
151. Scherzinger E., Lurz R., Turmaine M., Mangiarini L., Hollenbach B., Hasenbank R., Bates G.P., Davies S.W., Lehrach H., Wanker E.E. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 1997, 90:549-558.
152. Schilling G., Becher M.W., Sharp A.H., Jinnah H.A., Duan K., Kotzuk J.A., Slunt H.H., Ratovitski T., Cooper J.K., Jenkins N.A., Copeland N.G., Price D.L., Ross C.A., Borchelt D.R. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 1999, 8:397-407.
153. Sedvall G., Karlsson P., Lundin A., Anvret M., Suhara T., Halldin C., Farde L. Dopamine DI receptor number-a sensitive PET marker for early brain degeneration in Huntington's disease. Eur. Arch. Psychiatry Clin. Neurosci. 1994, 243:249-255.
154. Shimohata T., Nakajima T., Yamada M., Uchida C., Onodera O., Naruse S., Kimura T., Koide R., Nozaki K., Sano Y., Ishiguro H., Sakoe K., Ooshima T., Sato A., Ikeuchi T., Oyake M., Sato T., Aoyagi Y., Hozumi I., Nagatsu T., Takiyama Y., Nishizawa M., Goto J., Kanzawa I., Davidson I., Tanese N., Takahashi H., Tsuji S. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat. Genet. 2000, 26:29-36.
155. Shoulson I., Odoroff C., Oakes D., Behr J., Goldblatt D., Caine E., Kennedy J., Miller C., Bamford K., Rubin A., et al. A controlled clinical trial of baclofen as protective therapy in early Huntington's disease. Ann. Neurol. 1989, 25:252-259.
156. Steffan J.A., Kazantsev A., Spasic-Boskovic O., Greenwald M., Zhu Y.-Z., Gohler H., Wanker E., Bates G.P., Housman D.E., Thompson L.M. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:6763-6768.
157. Stenoien D.L., Cummings C.J., Adams H.P., Mancini M.G., Patel K., DeMartino G.N., Marcelli M., Weigel N.L., Mancini M.A. Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. Hum. Mol. Genet. 1999, 8:731-741.
158. Stott K., Blackburn J.M., Butler P.J., Perutz M. Incorporation of glutamine repeats makes protein oligomerize: implications for neurodegenerative diseases. Proc. Nat. Acad. Sci. U.S.A. 1995, 92:6509-6513.
159. Tabrizi S.J., Cleeter M.W., Xuereb J., Taanman J.W., Cooper J.M., Schapira A.H. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann. Neurol. 1999, 45:25-32.
160. Tabrizi S.J., Workman J., Hart P.E., Mangiarini L., Mahal A., Bates G., Cooper J.M., Schapira A.H. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann. Neurol. 2000, 47:80-86.
161. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001, 57:397-404. The Huntington Study Group.
162. Thomas L.B., Gates D.J., Ritchfield E.K., O'Brien T.F., Schweitzer J.B., Steindler D.A. DNA end labeling (TUNEL) in Huntington's disease and other neuropathological conditions. Exp. Neurol. 1995, 133:265-272.
163. Thornberry N.A., Lazebnik Y. Caspases: Enemies within. Science 1998, 281:1312-1316.
164. Timmers H.J., Swaab D.F., van de Nes J.A., Kremer H.P. Somatostatin 1-12 immunoreactivity is decreased in the hypothalamic lateral tuberal nucleus of Huntington's disease patients. Brain Res. 1996, 728:141-148.
165. Turjanski N., Weeks R., Dolan R., Harding A.E., Brooks D.J. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study. Brain 1995, 118:689-696.
166. Turmaine M., Raza A., Mahal A., Mangiarini L., Bates G.P., Davies S.W. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:8093-8097.
167. Ueno S., Maruki Y., Nakamura M., Tomemori Y., Kamae K., Tanabe H., Yamashita Y., Matsuda S., Kaneko S., Sano A. The gene encoding a newly discovered protein, chorein, is mutated in chorea-acanthocytosis. Nat Genet. 2001, 28:121-122.
168. Usdin M.T., Shelbourne P.F., Myers R.M., Madison D.V. Impaired synaptic plasticity in mice carrying the Huntington's disease mutation. Hum. Mol. Genet. 1999, 8:839-846.
169. Van Dijk J.F., van der Velde E.A., Roos R.A.C., Bruyn G.W. Juvenile Huntington's disease. Hum. Genet. 1986, 73:235-239.
170. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 1985, 44:559-577.
171. Vonsattel J.P., DiFiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 1998, 57:369-384.
172. Wadzinski B.E., Wheat W.H., Jaspers S., Peruski L.F., Lickteig R.L., Johnson G.L., Klemm D.J. Nuclear protein phosphatase 2A dephosphorylates protein kinase A-phosphorylated CREB and regulates CREB transcriptional stimulation. Mol. Cell Biol. 1993, 13:2822-2834.
173. Waelter S., Scherzinger E., Hasenbank R., Nordhoff E., Lurz R., Goehler H., Gauss C., Sathasivam K., Bates G.P., Lehrach H., Wanker E.E. The huntingtin interacting protein HIP1 is a clathrin and alpha-adaptin-binding protein involved in receptor-mediated endocytosis. Hum. Mol. Genet. 2001, 10:1807-1817.
174. Warrick J.M., Paulson H.L., Gray-Board G.L., Bui Q.T., Fischbeck K.H., Pittman R.N., Bonini N.M. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell 1998, 93(6):939-949.
175. Weeks R.A., Piccini P., Harding A.E., Brooks D.J. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann. Neurol. 1996, 40:49-54.
176. Weeks R.A., Cunningham V.J., Piccini P., Waters S., Harding A.E., Brooks D.J. 11C-diprenorphine binding in Hungtington's disease: a comparison of region of interest analysis with statistical parametric mapping. J. Cereb. Blood Flow Metab. 1997, 17:943-949.
177. Wellington C.L., Singaraja R., Ellerby L., Savill J., Roy S., Leavitt B., Cattaneo E., Hackam A., Sharp A., Thornberry N., Nicholson D.W., Bredesen D.E., Hayden M.R. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J. Biol. Chem. 2000, 275:19,831-19,838.
178. Wellington C.L., Ellerby L.M., Hackam A.S., Margolis R.L., Trifiro M.A., Singaraja R., McCutcheon K., Salvesen G.S., Propp S.S., Bromm M., Rowland K.J., Zhang T., Rasper D., Roy S., Thornberry N., Pinsky L., Kakizuka A., Ross C.A., Nicholson D.W., Bredesen D.E., Hayden M.R. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J. Biol. Chem. 1998, 273:9158-9167.
179. White J.K., Auerbach W., Duyao M.P., Vonsattel J.-P., Gusella J.F., Joyner A.L., MacDonald M.E. Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat. Genet. 1997, 17:404-410.
180. Wyttenbach A., Carmichael J., Swartz J., Furlong R.A., Narain Y., Rankin J., Rubinsztein D.C. Effects of heat shock, Hsp40 and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proc. Nat. Acad. Sci. U.S.A. 2000, 97:2898-2903.
181. Wyttenbach A., Swartz J., Kita H., Thykjaer T., Carmichael J., Bradley J., Brown R., Maxwell M., Schapira A., Orntoft T.F., Kato K., Rubinsztein D.C. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. Hum. Mol. Genet. 2001, 10:1829-1845.
182. Young A.B., Greenamyre J.T., Hollingsworth Z., Ablin R., D'Amato C., Shoulson I., Penney J.B. NMDA receptor losses in putamen from patients with Huntington's disease. Science 1988, 241:981-983.
183. Zeitlin S., Liu J.P., Chapman D.L., Papaioannou V.E., Efstratiadis A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homolog. Nat. Genet. 1995, 11:155-163.
184. Zeron M.M., Chen N., Moshaver A., Lee A.T., Wellington C.L., Hayden M.R., Raymond L.A. Mutant huntingtin enhances excitotoxic cell death. Mol. Cell Neurosci. 2001, 17:41-53.
185. Zuccato C., Ciammola A., Rigamonti D., Leavitt B.R., Goffredo D., Conti L., MacDonald M.E., Friedlander R.M., Silani V., Hayden M.R., Timmusk T., Sipione S., Cattaneo E. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001, 293:493-498.